NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division - Seite 2

"Joining forces with NovAccess Global will not just expand the quality of data sources available to both companies and improve our combined geographical reach, but will allow for CKN Ventures to drive a generation of new and enhanced targeted data sets by providing molecular and genomic sequencing capabilities from its Bangkok-based laboratory and wholly owned subsidiary, Phoenix Molecular," said CKN Ventures Director Supornchai Kongpatanakul, MD. "We view CKN's strengths in bioinformatics, molecular diagnostics, and the development of digital health systems to be complimentary to NovAccess Global's assets in therapeutics and precision medicine. Together, the two companies will leverage their combined talents to identify new breakthroughs in cancer and chronic disease management through this unique collaboration."

NovAccess Global intends to also use AI within these data sets to identify the most optimal antigens to use for dendritic cell vaccines. Antigens are the molecules that trigger the immune response, and they need to be specific for the tumor cells and not the normal cells. AI can analyze the genomic and proteomic data of tumor cells and find the most suitable antigens for each patient.

It is NovAccess Global's belief that AI can help to optimize the dose and timing of dendritic cell vaccines. The dose and timing of the vaccine can affect the efficacy and safety of the treatment. AI can use mathematical models and machine learning algorithms to predict the optimal dose and timing based on various factors such as the patient's characteristics, the tumor type and stage, and the immune status.

In partnering with NovAccess Global, CKN Ventures is positioned to support trials of the Company's therapeutic candidate in glioblastoma patients in both North America and Asia. Dr. Supornchai added, "Our proven capabilities in genomics and bioinformatic analysis will help to support NovAccess Global's trial design and assist in measuring patient response to this groundbreaking therapy while providing research and pharmaceutical entities with data on various variables such as biomarkers and clinical outcomes."

About NovAccess Global

NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics. Our goal is to discover, develop and bring to market novel and innovative medicine and medical devices to improve the quality of care for cancer and neurological patients.

NovAccess Global is currently developing a cancer vaccine therapy that enhances the patient's immune response against brain tumors. Our Company has a novel immunotherapeutic approach to treating brain tumor patients with glioblastoma, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient's tumor. Our platform technology focuses on enhancing the patient's immune cells to fight their unique cancer by utilizing the antigens specific to the patient's tumor. It is a meaningful technology that could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors. For more information, please visit novaccessglobal.com.